$ACHN News In focus: New highs premature? 9:03
Post# of 88933
Posted On: 06/20/2014 12:19:39 PM
$ACHN News
In focus: New highs premature? 9:03 p.m. June 18, 2014 - Lawrence G. McMillan
Achillion shares up; FDA lifts hold on hepatitis C drug 10:25 a.m. June 10, 2014 - Anna Prior
U.S. stock futures sink on shutdown fears 8:38 a.m. Sept. 30, 2013 - Barbara Kollmeyer
Zynga shares rise, Achillion drops after hours 5:51 p.m. July 1, 2013 - Wallace Witkowski
FDA puts Achillion Hep C drug on clinical hold 5:16 p.m. July 1, 2013 - MarketWatch.com
Five stocks making moves 3:12 p.m. Feb. 14, 2013 - The Trading Deck
Thursday’s top gaining & declining stocks 5:02 p.m. Sept. 27, 2012 - Greg Morcroft
Achillion sees progress in hepatitis C study 9:04 a.m. Sept. 27, 2012 - MarketWatch.com
Vertex to advance testing of oral HCV drug regimen 10:34 a.m. Sept. 25, 2012 - Val Brickates Kennedy
Wednesday’s biggest gaining and declining stocks 4:37 p.m. Sept. 19, 2012 - MarketWatch
Achillion, Idenix move on price target changes 10:29 a.m. Sept. 19, 2012 - Val Brickates Kennedy
Gilead boosted as analysts hike price targets 10:42 a.m. Sept. 17, 2012 - Val Brickates Kennedy
Thursday’s biggest gaining and declining stocks 4:47 p.m. Aug. 16, 2012 - MarketWatch
Idenix plunges 30% on HCV drug setback 12:56 p.m. Aug. 16, 2012 - Val Brickates Kennedy
Bristol’s bad news is good for rivals: analysts 5:52 p.m. Aug. 2, 2012 - Val Brickates Kennedy
Gilead shares boosted by Bristol-Myers drug news 11:24 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Bristol-Myers falls 7% on hepatitis C drug setback 10:09 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Stocks to watch Thursday: Annie’s, Rite Aid 5:02 p.m. June 6, 2012 - David B. Wilkerson
Achillion's chief medical officer resigns 4:19 p.m. June 6, 2012 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 4:23 p.m. May 21, 2012 - MarketWatch
Speculators On The Next HCV Acquisition Should Not Overlook Technological Platforms 10:25 a.m. Today - Seeking Alpha
Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog 10:33 a.m. June 18, 2014 - Zacks.com
Benzinga's Top #PreMarket Losers 7:12 a.m. June 18, 2014 - benzinga.com
Hepatitis C May Give A Big Boost To These Drug Stocks - If The FDA Approves 1:32 p.m. June 17, 2014 - Seeking Alpha
Achillion Set to See Shares Soar 7:44 a.m. June 17, 2014 - Barrons.com
Benzinga's Top #PreMarket Losers 7:18 a.m. June 17, 2014 - benzinga.com
Maxim's $22 Price Target On Achillion Is Far From Realistic 3:33 a.m. June 17, 2014 - Seeking Alpha
If Achillion Was Going To Be Taken Out At A Big Premium, Baupost Would Probably Own It 5:56 p.m. June 16, 2014 - Seeking Alpha
Why Achillion Pharmaceuticals (ACHN) Is Spiking Today 10:33 a.m. June 16, 2014 - TheStreet.com
Achillion Gets Massive Price Target Hike On HCV Drugs 10:27 a.m. June 16, 2014 - Investors Business Daily
Maxim Group Significantly Raises Achillion's PT, Shares Soar +15% 8:34 a.m. June 16, 2014 - benzinga.com
Mid-Afternoon Market Update: Markets Reverse Early Loses; Oil Continues To Rise On Overseas Worry 2:36 p.m. June 13, 2014 - benzinga.com
Mid-Morning Market Update: Markets Mostly Flat; Priceline To Acquire OpenTable For $103/Share 9:25 a.m. June 13, 2014 - benzinga.com
Morning Market Losers 8:44 a.m. June 13, 2014 - benzinga.com
Benzinga's Top #PreMarket Losers 7:12 a.m. June 13, 2014 - benzinga.com
Biotech ETFs – Keep Those Buyouts Coming! 9:14 a.m. June 12, 2014 - InvestorPlace.com
Achillion Pharmaceuticals (ACHN) in Focus: Stock Falls 6.4% - Tale of the Tape 8:36 a.m. June 12, 2014 - Zacks.com
Why Big Pharma Has No Interest In Achillion's 'Me Too' Hepatitis C Drug 8:30 a.m. June 12, 2014 - Seeking Alpha
Top Analyst Upgrades and Downgrades: Apache, Apple, HP, Qualcomm, Sprouts and More 7:58 a.m. June 12, 2014 - 247WallSt.com
Biotech Stocks Get Turbo Boost From Idenix Deal 6:45 p.m. June 11, 2014 - Seeking Alpha
Critical Alerts For Bank of America, Achillion Pharmaceuticals, Walmart, SunEdison, and Advanced Micro Devices Released By InvestorsObserver 9:31 a.m. June 17, 2014 - PR Newswire - PRF
If Achillion Pharmaceuticals (NASDAQ: ACHN) Investors Are Hoping for a Buyout, This is Not an Investment Strategy; Analyst Report by BrokerBank Securities, Inc. 7:00 a.m. June 13, 2014 - PR Newswire - PRF
Technical Update, Leadership Appointments, and Clinical Trial Results - Analyst Notes on Achillion, Nektar, CytRx, Galena and Receptos 5:20 a.m. June 12, 2014 - PR Newswire - PRF
Achillion to Present at Two Upcoming Investor Conferences 6:06 a.m. June 11, 2014 - GlobeNewswire
Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the Treatment of Chronic HCV 6:06 a.m. June 10, 2014 - GlobeNewswire
Biotech Equities under the Scanner -- Research on Halozyme Therapeutics, Medivation, Achillion Pharma, and Alexion Pharma 8:10 a.m. June 6, 2014 - PR Newswire - PRF
Biotech Equities Under Review -- Research on Achillion Pharma, Mast Therapeutics, Alkermes, and Momenta Pharma 1:30 p.m. May 9, 2014 - PR Newswire - PRF
Achillion Reports First Quarter 2014 Financial Results 6:06 a.m. May 7, 2014 - GlobeNewswire
Achillion to Present at Three Upcoming Investor Conferences 6:31 a.m. May 1, 2014 - GlobeNewswire
Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, for HCV 4:07 p.m. April 30, 2014 - GlobeNewswire
Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys 8:16 a.m. April 14, 2014 - PR Newswire - PRF
Morning Analysis on Top Gainers -- Research on Achillion Pharma, Microvision, Miller Energy Resources, and Bon-Ton Stores 11:24 a.m. March 25, 2014 - PR Newswire - PRF
Achillion Announces Oral Presentations Given at APASL 2014 Detailing Clinical Activity of ACH-3102, Second-Generation NS5A Inhibitor, Against Genotype 1b HCV 6:05 a.m. March 14, 2014 - GlobeNewswire
Achillion Reports 2013 Fourth Quarter and Year-End Financial Results 7:05 a.m. March 7, 2014 - GlobeNewswire
Achillion to Present at Two Upcoming Investor Conferences 7:00 a.m. Feb. 10, 2014 - GlobeNewswire
Stock Price Movements, FDA Applications, Appointments, and Clinical Study Updates - Research Report on Alere, ARCA, Achillion, Idenix Pharmaceuticals, and Receptos 9:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones 7:25 a.m. Jan. 13, 2014 - GlobeNewswire
ACHILLION PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Achillion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ACHN 12:53 p.m. Dec. 6, 2013 - PR Newswire
Increased Quarterly Dividends, HIV Elimination Efforts, Advanced Treatment Options, and Conference Participations - Research Report on Merck, Varian, Mylan, Achillion, and Abiomed 9:00 a.m. Dec. 4, 2013 - PR Newswire
ACHN, CTIC, DRYS and FREE added to NASDAQ Active Stock Watch List at GSR 11:01 a.m. Dec. 2, 2013 - ACCESSWIRE
In focus: New highs premature? 9:03 p.m. June 18, 2014 - Lawrence G. McMillan
Achillion shares up; FDA lifts hold on hepatitis C drug 10:25 a.m. June 10, 2014 - Anna Prior
U.S. stock futures sink on shutdown fears 8:38 a.m. Sept. 30, 2013 - Barbara Kollmeyer
Zynga shares rise, Achillion drops after hours 5:51 p.m. July 1, 2013 - Wallace Witkowski
FDA puts Achillion Hep C drug on clinical hold 5:16 p.m. July 1, 2013 - MarketWatch.com
Five stocks making moves 3:12 p.m. Feb. 14, 2013 - The Trading Deck
Thursday’s top gaining & declining stocks 5:02 p.m. Sept. 27, 2012 - Greg Morcroft
Achillion sees progress in hepatitis C study 9:04 a.m. Sept. 27, 2012 - MarketWatch.com
Vertex to advance testing of oral HCV drug regimen 10:34 a.m. Sept. 25, 2012 - Val Brickates Kennedy
Wednesday’s biggest gaining and declining stocks 4:37 p.m. Sept. 19, 2012 - MarketWatch
Achillion, Idenix move on price target changes 10:29 a.m. Sept. 19, 2012 - Val Brickates Kennedy
Gilead boosted as analysts hike price targets 10:42 a.m. Sept. 17, 2012 - Val Brickates Kennedy
Thursday’s biggest gaining and declining stocks 4:47 p.m. Aug. 16, 2012 - MarketWatch
Idenix plunges 30% on HCV drug setback 12:56 p.m. Aug. 16, 2012 - Val Brickates Kennedy
Bristol’s bad news is good for rivals: analysts 5:52 p.m. Aug. 2, 2012 - Val Brickates Kennedy
Gilead shares boosted by Bristol-Myers drug news 11:24 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Bristol-Myers falls 7% on hepatitis C drug setback 10:09 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Stocks to watch Thursday: Annie’s, Rite Aid 5:02 p.m. June 6, 2012 - David B. Wilkerson
Achillion's chief medical officer resigns 4:19 p.m. June 6, 2012 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 4:23 p.m. May 21, 2012 - MarketWatch
Speculators On The Next HCV Acquisition Should Not Overlook Technological Platforms 10:25 a.m. Today - Seeking Alpha
Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog 10:33 a.m. June 18, 2014 - Zacks.com
Benzinga's Top #PreMarket Losers 7:12 a.m. June 18, 2014 - benzinga.com
Hepatitis C May Give A Big Boost To These Drug Stocks - If The FDA Approves 1:32 p.m. June 17, 2014 - Seeking Alpha
Achillion Set to See Shares Soar 7:44 a.m. June 17, 2014 - Barrons.com
Benzinga's Top #PreMarket Losers 7:18 a.m. June 17, 2014 - benzinga.com
Maxim's $22 Price Target On Achillion Is Far From Realistic 3:33 a.m. June 17, 2014 - Seeking Alpha
If Achillion Was Going To Be Taken Out At A Big Premium, Baupost Would Probably Own It 5:56 p.m. June 16, 2014 - Seeking Alpha
Why Achillion Pharmaceuticals (ACHN) Is Spiking Today 10:33 a.m. June 16, 2014 - TheStreet.com
Achillion Gets Massive Price Target Hike On HCV Drugs 10:27 a.m. June 16, 2014 - Investors Business Daily
Maxim Group Significantly Raises Achillion's PT, Shares Soar +15% 8:34 a.m. June 16, 2014 - benzinga.com
Mid-Afternoon Market Update: Markets Reverse Early Loses; Oil Continues To Rise On Overseas Worry 2:36 p.m. June 13, 2014 - benzinga.com
Mid-Morning Market Update: Markets Mostly Flat; Priceline To Acquire OpenTable For $103/Share 9:25 a.m. June 13, 2014 - benzinga.com
Morning Market Losers 8:44 a.m. June 13, 2014 - benzinga.com
Benzinga's Top #PreMarket Losers 7:12 a.m. June 13, 2014 - benzinga.com
Biotech ETFs – Keep Those Buyouts Coming! 9:14 a.m. June 12, 2014 - InvestorPlace.com
Achillion Pharmaceuticals (ACHN) in Focus: Stock Falls 6.4% - Tale of the Tape 8:36 a.m. June 12, 2014 - Zacks.com
Why Big Pharma Has No Interest In Achillion's 'Me Too' Hepatitis C Drug 8:30 a.m. June 12, 2014 - Seeking Alpha
Top Analyst Upgrades and Downgrades: Apache, Apple, HP, Qualcomm, Sprouts and More 7:58 a.m. June 12, 2014 - 247WallSt.com
Biotech Stocks Get Turbo Boost From Idenix Deal 6:45 p.m. June 11, 2014 - Seeking Alpha
Critical Alerts For Bank of America, Achillion Pharmaceuticals, Walmart, SunEdison, and Advanced Micro Devices Released By InvestorsObserver 9:31 a.m. June 17, 2014 - PR Newswire - PRF
If Achillion Pharmaceuticals (NASDAQ: ACHN) Investors Are Hoping for a Buyout, This is Not an Investment Strategy; Analyst Report by BrokerBank Securities, Inc. 7:00 a.m. June 13, 2014 - PR Newswire - PRF
Technical Update, Leadership Appointments, and Clinical Trial Results - Analyst Notes on Achillion, Nektar, CytRx, Galena and Receptos 5:20 a.m. June 12, 2014 - PR Newswire - PRF
Achillion to Present at Two Upcoming Investor Conferences 6:06 a.m. June 11, 2014 - GlobeNewswire
Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the Treatment of Chronic HCV 6:06 a.m. June 10, 2014 - GlobeNewswire
Biotech Equities under the Scanner -- Research on Halozyme Therapeutics, Medivation, Achillion Pharma, and Alexion Pharma 8:10 a.m. June 6, 2014 - PR Newswire - PRF
Biotech Equities Under Review -- Research on Achillion Pharma, Mast Therapeutics, Alkermes, and Momenta Pharma 1:30 p.m. May 9, 2014 - PR Newswire - PRF
Achillion Reports First Quarter 2014 Financial Results 6:06 a.m. May 7, 2014 - GlobeNewswire
Achillion to Present at Three Upcoming Investor Conferences 6:31 a.m. May 1, 2014 - GlobeNewswire
Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, for HCV 4:07 p.m. April 30, 2014 - GlobeNewswire
Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys 8:16 a.m. April 14, 2014 - PR Newswire - PRF
Morning Analysis on Top Gainers -- Research on Achillion Pharma, Microvision, Miller Energy Resources, and Bon-Ton Stores 11:24 a.m. March 25, 2014 - PR Newswire - PRF
Achillion Announces Oral Presentations Given at APASL 2014 Detailing Clinical Activity of ACH-3102, Second-Generation NS5A Inhibitor, Against Genotype 1b HCV 6:05 a.m. March 14, 2014 - GlobeNewswire
Achillion Reports 2013 Fourth Quarter and Year-End Financial Results 7:05 a.m. March 7, 2014 - GlobeNewswire
Achillion to Present at Two Upcoming Investor Conferences 7:00 a.m. Feb. 10, 2014 - GlobeNewswire
Stock Price Movements, FDA Applications, Appointments, and Clinical Study Updates - Research Report on Alere, ARCA, Achillion, Idenix Pharmaceuticals, and Receptos 9:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones 7:25 a.m. Jan. 13, 2014 - GlobeNewswire
ACHILLION PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Achillion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ACHN 12:53 p.m. Dec. 6, 2013 - PR Newswire
Increased Quarterly Dividends, HIV Elimination Efforts, Advanced Treatment Options, and Conference Participations - Research Report on Merck, Varian, Mylan, Achillion, and Abiomed 9:00 a.m. Dec. 4, 2013 - PR Newswire
ACHN, CTIC, DRYS and FREE added to NASDAQ Active Stock Watch List at GSR 11:01 a.m. Dec. 2, 2013 - ACCESSWIRE
(0)
(0)Scroll down for more posts ▼